← Leaderboards
Yevgeny Brudno
North Carolina State University Raleigh
$4,485,709
Attributed
$4,763,703
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,763,703 · 5
By mechanism
R37$2,020,234 · 1
R01$1,222,173 · 1
R33$780,610 · 1
R21$740,686 · 2
Top collaborators
- Paul A Dayton2 shared
- Pritha Agarwalla1 shared
Most similar at North Carolina State University Raleigh
Same institution · by research overlap
- Alper Bozkurt$430,466
- John Baratta$223,357
- Xipeng Shen$223,357
- Yong Zhu$223,357
- Pritha Agarwalla$250,614
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorImplantTechnologyPreventMediatingCostManufacturing ProcessBiocompatible MaterialsCellsPhenotypeCd28 GeneEngraftmentCar T Cell TherapyChimeric Antigen Receptor T CellsSuccessIn VivoAlginatesResponseRetroviral VectorDrug Delivery SystemsCellular TransductionBioscaffoldEncapsulatedMedical
Grant awards (17)
Bioinstructive Scaffolds for Potent and Affordable CAR-T Cell Therapy Against Brain Tumors$634,205
R01 · FY2025 · CA · contact PI
MASTER Scaffolds for Rapid, Single-Step Manufacture and Prototyping of CAR-T cells$401,164
R33 · FY2025 · CA · contact PI
Biomaterial Scaffolds for Ex Vivo and In Situ CAR-T Cell Production$322,157
R37 · FY2025 · CA · contact PI
Biomaterial Scaffolds for Ex Vivo and In Situ CAR-T Cell Production$439,825
R37 · FY2024 · CA · contact PI
Biomaterial Scaffolds for In Vivo CAR T Cell Manufacture$199,164
R21 · FY2024 · CA · contact PI
Biomaterial Scaffolds for Ex Vivo and In Situ CAR-T Cell Production$5,781
R37 · FY2024 · CA · contact PI
Bioinstructive Scaffolds for Potent and Affordable CAR-T Cell Therapy Against Brain Tumors$401,426
R01 · FY2023 · CA · contact PI
Biomaterial Scaffolds for Ex Vivo and In Situ CAR-T Cell Production$376,324
R37 · FY2023 · CA · contact PI
MASTER Scaffolds for Rapid, Single-Step Manufacture and Prototyping of CAR-T cells$261,931
R33 · FY2023 · CA · contact PI
Bioinstructive Scaffolds for Potent and Affordable CAR-T Cell Therapy Against Brain Tumors$186,542
R01 · FY2023 · CA · contact PI
Biomaterial Scaffolds for In Vivo CAR T Cell Manufacture$172,076
R21 · FY2023 · CA · contact PI
MASTER Scaffolds for Rapid, Single-Step Manufacture and Prototyping of CAR-T cells$117,515
R33 · FY2023 · CA · contact PI
Biomaterial Scaffolds for Ex Vivo and In Situ CAR-T Cell Production$85,053
R37 · FY2023 · CA · contact PI
Biomaterial Scaffolds for Ex Vivo and In Situ CAR-T Cell Production$384,005
R37 · FY2022 · CA · contact PI
Biomaterial Scaffolds for Ex Vivo and In Situ CAR-T Cell Production$407,089
R37 · FY2021 · CA · contact PI
Image-guided, ultrasound-enhanced long-term intracranial drug delivery$201,516
R21 · FY2021 · CA · contact PI
Image-guided, ultrasound-enhanced long-term intracranial drug delivery$167,930
R21 · FY2020 · CA · contact PI